Abstract
The most aggressive Skin Cancers is Melanoma, which has a high mortality rate and increasing incidence. The BRAFV600E protein ihibitors, the most recurrent mutation in Melanoma, came at the beginning of the decade as promising treatments, however, the high cost, adverse effects and frequent tumor resistance are limiting its therapeutic success. Given this, there is an urgent need to disco…